97193 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
MUSCLE TARGETING COMPLEXES FOR TREATING DYSTROPHINOPATHIES
#2VHH ANTIBODIES AND USES THEREOF
#3CONJUGATES COMPRISING BIS-MSPT LINKER
#4GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS FOR PRODUCING HEAVY-CHAIN ANTIBODIES
#5STABILIZED IMMUNOGLOBULIN DOMAINS
#6ANTIGEN-BINDING MOLECULES WITH INCREASED PENETRATION INTO AND RETENTION IN BRAIN, AND METHODS FOR USE THEREOF
#7NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#8MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#9ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
#10TRANSFERRIN RECEPTOR BINDING PROTEINS FOR TREATING BRAIN TUMORS
#11COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
#12STABILIZED BINDING MOLECULE
#13ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING
#14BISPECIFIC BINDING MOLECULE
#15ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF
#16MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#17Nucleic Acid Molecule, Vector, Recombinant Cells, and Drug for Treating Central Nervous System Disease
#18PRNP RNAi AGENTS
#19BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
#20MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY
#21ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF
#22PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING
#23MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#24COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#25COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#26TRANSFERRIN RECEPTOR-BINDING DOMAINS AND PROTEINS COMPRISING THE SAME
#27MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MUSCULAR DYSTROPHY
#28MULTISPECIFIC BINDING MOLECULES AND METHODS OF USE THEREOF
#29RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use
#30ANTIBODY-OLIGONUCLEOTIDE CONJUGATE AND ANTIBODY-PEPTIDE-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#31BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#32MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#33METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#34CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION
#35METHODS AND COMPOSITIONS FOR RE-DOSING AAV USING ANTI-CD40 ANTAGONISTIC ANTIBODY TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE
#36MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#37MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#38TRANSFERRIN RECEPTOR ANTIGEN-BINDING DOMAINS AND USES THEREFOR
#39Anti-CD98hc VNARs for Crossing the Blood Brain Barrier and Type IV VNAR Libraries
#40THERAPEUTIC AGENT FOR NK-CELL TUMOR
#41GLYCOPROTEIN HAVING REDUCED NUMBER OF MANNOSE-6-PHOSPHATES
#42BISPECIFIC ANTIBODY BINDING TO TfR
#43SIL-6R AND CTGF BINDING PROTEINS AND METHODS OF USE THEREOF
#44MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#45SARM1 RNAi AGENTS
#46DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING MYOTONIC DYSTROPHY
#47MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#48METHODS AND COMPOSITIONS FOR USING PLASMA CELL DEPLETING AGENTS AND/OR B CELL DEPLETING AGENTS TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE AND ENABLE AAV TRANSDUCTION AND RE-DOSING
#49MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#50ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF
#51BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#52BISPECIFIC ANTIBODIES AND METHODS OF USE
#53MONOVALENT ANTI-TREM2 BINDING MOLECULES AND METHODS OF USE THEREOF
#54GENE THERAPY FOR DISEASES WITH CNS MANIFESTATIONS
#55COMPOSITIONS AND METHODS FOR MODULATING NaV1.8
#56METHODS AND COMPOSITIONS FOR TARGETED DELIVERY OF INTRACELLULAR BIOLOGICS
#57METHODS AND COMPOSITIONS FOR THERAPEUTIC PROTEIN DELIVERY
#58MULTISPECIFIC ANTIBODIES AND USES THEREOF
#59MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#60MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#61MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#62MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES
#63NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#64ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY
#65MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#66FUSION PROTEINS COMPRISING ALPHA-L-IDURONIDASE ENZYMES AND METHODS
#67MULTISPECIFIC ANTIBODIES AND USES THEREOF
#68MULTISPECIFIC ANTIBODIES AND USES THEREOF
#69DEIMMUNIZED VNAR DOMAINS AND SCAFFOLDS
#70ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 45 SKIPPING
#71COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
#72HIGH AFFINITY HUMAN AND MONKEY SPECIFIC TFR-1 VNARS
#73MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#74ANTIBODY-DRUG CONJUGATE
#75MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#76Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
#77Fusion Protein of Anti-Transferrin Receptor Antibody and Physiologically Active Protein for Safe Gene Therapy
#78TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS
#79ANTI-TFR:ACID SPHINGOMYELINASE FOR TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
#80ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE
#81TARGETED VESICLE COMPOSITIONS AND METHODS
#82Novel Anti-Human Transferrin Receptor Antibody Capable of Penetrating Blood-Brain Barrier
#83DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING DYSTROPHINOPATHIES
#84Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies
#85Muscle targeting complexes and uses thereof for treating dystrophinopathies
#86COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#87Muscle targeting complexes and uses thereof for treating dystrophinopathies
#88Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#89PROTEINS COMPRISING BLOOD BRAIN BARRIER (BBB)-BINDING DOMAINS WITHIN CONSTANT DOMAINS
#90MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#91MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#92TFR ANTIGEN BINDING PROTEINS AND USES THEREOF
#93TREM2 ANTIGEN BINDING PROTEINS AND USES THEREOF
#94ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING
#95MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#96Methods of Treating Neurologic Disorders
#97NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#98ROS (REACTIVE OXYGEN SPECIES) PRODUCTION ENHANCING AGENT
#99MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#100MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#101BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#102ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY HAVING IMPROVED BLOOD-BRAIN-BARRIER PERMEABILITY, AND MULTI-SPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION WHICH USE SAME
#103COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#104Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
#105OLIGONUCLEOTIDE CONJUGATES TARGETED TO THE TRANSFERRIN RECEPTOR
#106Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy
#107METHOD FOR DETERMINING MEDICINAL EFFECT OR SENSITIVITY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY
#108COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#109Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
#110TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
#111Methods of engineering transferrin receptor binding polypeptides
#112METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#113Pharmaceutical Composition for Treatment of Mucopolysaccharidosis Type 1
#114Fusion Protein Containing BDNF
#115TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES
#116Method for Delivering Drug to Muscle
#117Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#118ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
#119TRANSFERRIN RECEPTOR BINDING PROTEINS
#120METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN
#121MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#122MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#123ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE
#124Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#125COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION
#126HUMANIZED ANTIBODIES AGAINST PAIRED HELICAL FILAMENT TAU AND USES THEREOF
#127Method for Producing Fusion Protein
#128Method for Producing Antibody-Lysosomal Enzyme Fusion Protein
#129ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF
#130METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#131ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
#132Compositions and methods of treating facioscapulohumeral muscular dystrophy
#133Compositions and methods of treating facioscapulohumeral muscular dystrophy
#134ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
#135MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#136Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
#137Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
#138Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity
#139Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#140Muscle targeting complexes and uses thereof for treating dystrophinopathies
#141TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES
#142ANTI-TFR:PAYLOAD FUSIONS AND METHODS OF USE THEREOF
#143IN VIVO METHODS FOR SELECTING PEPTIDES THAT CROSS THE BLOOD BRAIN BARRIER, RELATED COMPOSITIONS AND METHODS OF USE
#144ANTI-BRDU ANTIBODIES AND METHODS OF USE
#145Type-II VNAR polypeptides which bind human TfR-1, encoding nucleic acids thereof and method of use thereof
#146ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#147ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#148FAB HIGH MANNOSE GLYCOFORMS
#149Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
#150AFFINITY-BASED METHODS FOR USING TRANSFERRIN RECEPTOR-BINDING PROTEINS
#151BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#152Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
#153Compositions and methods of treating facioscapulohumeral muscular dystrophy
#154ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE
#155COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE
#156Mutant of alpha-N-Acetylglucosaminidase
#157Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#158Site-specific antibody conjugation and its use
#159Compositions and methods of treating facioscapulohumeral muscular dystrophy
#160Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#161Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#162Muscle targeting complexes and uses thereof for treating dystrophinopathies
#163NANOPARTICLE COMPLEX WITH DEFINED SIZES
#164Anti-transferrin receptor antibody and uses thereof
#165ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF
#166THERAPEUTIC DRUG FOR CARCINOMATOUS PERITONITIS
#167Preparation of fetal nucleated red blood cells (NRBCs) for diagnostic testing
#168Methods of engineering transferrin receptor binding polypeptides
#169Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide
#170BBB-TARGETED GAA DELIVERED AS GENE THERAPY TREATS CNS AND MUSCLE IN POMPE DISEASE MODEL MICE
#171THERAPEUTIC DRUG FOR POLYCYTHEMIA
#172Anti-transferrin receptor antibodies with tailored affinity
#173TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE
#174BINDING MOLECULES WITH MODIFIED J-CHAIN
#175Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
#176MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#177ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS
#178Transferrin receptor (TFR)-selective binding peptides capable of crossing the blood brain barrier, encoding nucleic acids thereof and methods of use thereof
#179TRANSFERRIN RECEPTOR 1 TARGETING FOR CARCINOGENESIS PREVENTION
#180COMPOSITIONS AND METHODS FOR DETECTING CELLS UNDERGOING FERROPTOSIS USING AN ANTIBODY
#181ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
#182METHOD FOR PRODUCING MULTISPECIFIC ANTIBODIES
#183Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#184MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY
#185ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF
#186MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#187USE OF ANTIBODY DRUG CONJUGATES COMPRISING TUBULIN DISRUPTING AGENTS TO TREAT SOLID TUMOR
#188ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF
#189Compositions and methods of treating facioscapulohumeral muscular dystrophy
#190MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#191FUSION PROTEINS FOR SELECTIVELY DEPLETING ANTIGEN-SPECIFIC ANTIBODIES
#192Anti-transferrin receptor antibody and uses thereof
#193Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness
#194Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
#195Anti-transferrin receptor (TFR) antibody and uses thereof
#196Muscle targeting complexes and uses thereof for treating dystrophinopathies
#197COMPOSITIONS AND METHODS FOR DETECTING CELLS UNDERGOING FERROPTOSIS USING AN ANTIBODY
#198COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING
#199MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY
#200FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS
#201AGENT FOR INHIBITING IRON UPTAKE INTO CELLS
#202Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
#203Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#204Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
#205ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS OF USE THEREOF
#206METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES
#207Muscle targeting complexes and uses thereof for treating dystrophinopathies
#208REDUCTION OF APPLICATION-RELATED SIDE REACTION OF A THERAPEUTIC ANTIBODY
#209VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET THE BLOOD BRAIN BARRIER AND METHODS OF USE
#210Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
#211Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy
#212Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
#213Muscle targeting complexes and uses thereof for treating dystrophinopathies
#214Method of treating a tumor using anti-TfR antibodies
#215Transferrin receptor-binding molecules, conjugates thereof and their uses
#216Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#217In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
#218Muscle targeting complexes and uses thereof for treating dystrophinopathies
#219LYSOSOMAL STORAGE DISORDER BIOMARKERS AND METHODS OF USE THEREOF
#220Bifunctional molecules for lysosomal targeting and related compositions and methods
#221Bispecific antibody binding to TfR
#222ENGINEERED BISPECIFIC PROTEINS
#223Transferrin receptor (TfR)-selective binding peptides capable of crossing the blood brain barrier and methods of use thereof
#224TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERS
#225Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA
#226Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#227Method for determining the amount of a therapeutic antibody in the brain
#228MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING HYPERTROPHIC CARDIOMYOPATHY
#229MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
#230MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING CENTRONUCLEAR MYOPATHY
#231Super Versatile Method for Imparting New Binding Specificity to Antibody
#232MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE
#233Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
#234MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#235MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#236MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#237Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#238BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#239Low Affinity Blood Brain Barrier Receptor Antibodies and Uses Thereof
#240Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
#241MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#242Anti-transferrin receptor antibodies and uses thereof
#243Muscle targeting complexes and uses thereof for treating dystrophinopathies
#244Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#245ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE
#246Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4
#247Fusion proteins comprising enzyme replacement therapy enzymes
#248ANTIBODIES AND USES THEREOF
#249ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
#250ANTIBODY-DRUG CONJUCATES AND THEIR USES FOR THE TREATMENT OF CANCER
#251Anti-transferrin receptor antibodies and uses thereof
#252TRANSFERRIN RECEPTOR-BINDING POLYPEPTIDES AND USES THEREOF
#253ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#254Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
#255Aqueous pharmaceutical composition
#256Stabilized immunoglobulin domains
#257Method for Delivering Drug to Muscle
#258METHODS OF QUALITATIVELY AND/OR QUANTITATIVELY ANALYZING PROPERTIES OF ACTIVATABLE ANTIBODIES AND USES THEREOF
#259Methods and compositions for therapeutic protein delivery
#260Anti-transferrin receptor antibodies and uses thereof
#261Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
#262TfR selective binding compounds and related methods
#263TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE
#264Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein
#265REDUCTION OF APPLICATION-RELATED SIDE REACTION OF A THERAPEUTIC ANTIBODY
#266AFFINITY-BASED METHODS FOR USING TRANSFERRIN RECEPTOR-BINDING PROTEINS
#267FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES
#268Binding molecules with modified J-chain
#269FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS
#270Engineered transferrin receptor binding polypeptides
#271BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#272METHOD FOR PRODUCING MULTISPECIFIC ANTIBODIES
#273Human bladder cancer marker AG-CD71 and antibody ABC71 and application thereof
#274POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS
#275Antibody-ALK5 inhibitor conjugates and their uses
#276Anti-transferrin receptor antibodies and methods of use
#277Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds
#278Methods for reducing side effects of immunotherapy
#279MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES
#280Anti-transferrin receptor antibodies with tailored affinity
#281Tissue-specific Wnt signal enhancing molecules and uses thereof
#282COMPOSITIONS AND METHODS FOR NON-MYELOABLATIVE CONDITIONING
#283Fusion proteins (Seldegs) for selectively depleting antigen-specific antibodies and methods of use thereof
#284Anti-BRDU antibodies and methods of use
#285Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
#286GLYCOSYLATED TRANSFERRIN RECEPTOR 1 TUMOR ANTIGEN
#287USE OF THE CD71 RECEPTOR IN THE PROGNOSIS AND TREATMENT OF ENDOMETRIOSIS
#288Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
#289Anti-alpha-synuclein antibodies and methods of use
#290Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
#291BLOOD BRAIN BARRIER SHUTTLE
#292Recombinant polypeptide production methods
#293Fusion proteins comprising enzyme replacement therapy enzymes
#294ANTIBODY-DRUG CONJUGATE
#295Method for producing antibody fusion protein
#296Brain delivery protein
#297Low affinity blood brain barrier receptor antibodies and uses thereof
#298Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
#299In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
#300ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF